4 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
year worldwide, with an estimated societal cost of $60 billion.
3CL inhibitor CDI-988 has shown pan-viral activity against multiple norovirus strains
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
treatments or vaccines. Norovirus afflicts an estimated 685 million people annually at an estimated societal cost of $60 billion. About 200 million cases
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
and Prevention (CDC), an estimated 685 million cases and an estimated 200,000 deaths are attributed to norovirus each year worldwide, with an estimated societal
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
each year worldwide, with an estimated societal cost of $60 billion.
Hepatitis C Program
We are seeking a partner to advance development of CC-31244
- Prev
- 1
- Next